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Abstract
Purpose: Ovarian cancer (OC) leads to poor survival rates mainly due to late stage detection
and innate or acquired resistance to chemotherapy. Thus, efforts have been made to exploit the
estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) to treat OC.
However, patients eventually become resistant to these treatments as well. HER2 overexpres-
sion contributes to the acquired resistance to ER-targeted treatment. Trastuzumab treatment, on
the other hand, can result in increased expression of ER, which, in turn, increases the sensitivity
of the tumors towards anti-estrogen therapy. More insight into the crosstalk between ER and
HER2 signaling could improve our knowledge about acquired resistance in ovarian cancer. The
aim of this study was to evaluate whether PET could be used to detect changes in ER
expression induced by HER2-targeted treatment in vivo.
Procedures: Male athymic nude mice were subcutaneously (sc) inoculated with 106 SKOV3
human ovarian cancer cells (HER2+/ER+). Two weeks after inoculation, tumor-bearing mice
were treated intraperitoneally with either vehicle, the HER2 antibody trastuzumab (20 mg/kg, 2×/
week), or the HER2-tyrosine kinase inhibitor lapatinib (40 mg/kg, 5 days/week) for 2 weeks.
Thereafter, ER expression in the tumor was assessed by PET imaging with 16α-[18F]-fluoro-17β-
estradiol ([18F]FES). Tumors were excised for ex vivo ER and HER2 measurement with Western
blotting and immunohistochemistry.
Results: All treatments led to smaller tumors than vehicle-treated tumors. Higher [18F]FES
maximum standardize tumor uptake (SUVmax) was observed in animals treated with
trastuzumab (+ 29 %, P = 0.002) or lapatinib (+ 20 %, P = 0.096) than in vehicle-treated controls.
PET results were in agreement with ex vivo analyses.
Conclusion: FES-PET imaging can detect changes in ER expression induced by HER2-targeted
treatment and therefore can be used to investigate the crosstalk between ER and HER2 in a
noninvasive manner.
Key words: Positron emission tomography, Estrogen receptor, Human epidermal growth factor
receptor, Crosstalk, [18F]FES, Imaging
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Introduction
Ovarian cancer is often detected at a late stage, leading to
poor survival rates. Despite a favorable initial response to
chemotherapy, epithelial ovarian cancer (EOC) remains
with a high rate of recurrence. Efforts have been made to
exploit the estrogen dependency of ovarian cancer cells to
treat EOC with endocrine therapies. In contrast to other
hormonal-dependent cancers, such as breast cancer, anti-
estrogen therapies only proved to be successful in a small
number of ovarian cancer (OC) patients, and eventually,
most patients acquire resistance towards endocrine treat-
ment [1, 2]. The molecular mechanisms contributing to the
development of this spontaneous or acquired resistance are
not yet completely elucidated. Increasing evidence sug-
gests that aberrant activation of alternative signaling
cascades, such as growth factor-mediated signaling, can
provide the proliferation and survival signals to circumvent
the effects of endocrine treatment [3]. Expression of the
human epidermal growth factor receptor 2 (HER2) in
ovarian cancer has been associated with an advanced stage
of the disease, a higher recurrence rate, and shorter
survival rate [4, 5].
HER2-targeted therapies, including the antibody
trastuzumab and the tyrosine kinase inhibitor lapatinib,
have shown some efficacy towards certain HER2-
overexpressing ovarian cancers, but eventually acquired
resistance to these therapies was also observed [6].
Trastuzumab treatment can increase the expression of ER
by tumor cells, which, in turn, increases the sensitivity of
the tumors towards anti-estrogen therapy [7]. These results
suggest that there is a treatment-induced crosstalk between
estrogen receptors (ER) and HER-2 signaling pathways.
Thus, a better understanding of this crosstalk might
contribute to optimal treatment selection.
To obtain more insight into the ER-HER2 crosstalk, a
quantitative assessment of the expression levels of these
receptors in tumor lesions can be very useful. Currently,
ER and HER2 expression are usually determined ex vivo
in the primary tumor or a biopsy of a metastasis.
However, the receptor status of metastases may differ
from that in the primary tumor and can differ across
metastases within a single patient [8]. In addition, receptor
expression in the tumor lesions can change over time,
either spontaneously or due to treatment. Thus, biopsy
results only capture a part of the picture. In contrast to a
biopsy, functional imaging techniques, such as positron
emission tomography (PET) with 16α-[18F]-fluoro-17β-
estradiol ([18F]FES) as the tracer, can noninvasively
visualize the ER expression across all tumor lesions
throughout the body, respectively. Thus, PET might be
used to monitor the receptor status of all tumor lesions in
one patient simultaneously. The aim of this preclinical
study was, therefore, to evaluate whether [18F]FES-PET
could be used for the in vivo detection of changes in ER
expression induced by HER2-targeted treatment.
Materials and Methods
Cell Lines and Animals
The human ovarian cancer cell line SKOV3 (American
Type Culture Collection) was grown in Dulbecco’s Modi-
fied Eagle Medium (DMEM)-high glucose cell culture
medium, supplemented with 10 % fetal calf serum. Cells
were cultured at 37 °C in a humidified atmosphere of 95 %
air and 5 % CO2 (v/v). SKOV3 cells express both ER and
HER2, but are not dependent on estrogens for survival and
proliferation. Thus in this study, non-castrated athymic
nude male mice (Hsd, Athymic nude-Foxn1nu, 6–8 weeks
old, n = 31) were used to exclude any effect of the highly
variable circulating estrogen levels during the menstrual
cycle in females on PET tracer binding. We decided not to
use ovariectomized female mice, since this is a proof-of-
concept study and wanted to minimize animal discomfort.
Since the estrogen levels are much lower in male than in
female mice and consequently have negligible impact on
PET imaging results, we decided not to castrate the male
mice [9]. Mice were obtained from Envigo (formerly
Harlan, Lelystad, The Netherlands), and upon arrival, they
were provided with standard laboratory chow and tap water
ad libitum. All studies were carried out in compliance with
the Dutch regulations for animal experiments. The protocol
was approved by the Institutional Animal Care and Use
Committee of the University Medical Center Groningen
(protocol number: DEC 6657C). After at least 1 week of
acclimatization, SKOV3 cells (1 × 106 cells in a 1:1 mixture
of Matrigel and DMEM-high with 10 % fetal calf serum)
were subcutaneously (sc) injected into the upper back of the
mice. Two weeks after inoculation, palpable tumor nodules
had formed in most of the animals. Due to the ulceration of
the tumors, 5 animals had to be sacrificed before the
beginning of treatment.
Tumor Volumes and Therapeutic Regimens
All treatments were started 2 weeks after tumor inoculation.
SKOV3 tumor-bearing mice were randomly assigned to a
treatment group: (1) trastuzumab (n = 8, 20 mg/kg intraper-
itoneally (ip)) [7] or vehicle (n = 6, saline) twice a week or
(2) lapatinib (n = 6, 40 mg/kg ip) [10] or vehicle (n = 6,
saline) 5 days/week. Tumor diameters were measured with a
caliper, and tumor volume was calculated using the
following formula: [length × (width)2]/2. Relative tumor
volumes were calculated for each individual tumor by
dividing the tumor volume at the end of the treatment by
the tumor volume at the beginning of the treatment.
PET and CT Imaging
[18F]FES was produced as previously described [11]. Imaging
was conducted using a micro-PET Focus 220 rodent scanner
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(CTI Siemens). In mice that were treated with either trastuzumab
(ip, n = 8), lapatinib (ip, n = 6), or saline (ip, n = 6), [18F]FES
(13.7 ± 1.9 MBq) was administered via penile vein injection
(100 μl). Thirty minutes post-injection, a static emission scan
was acquired for 30 min. After completion of the PET scan, the
animals were sacrificedwith an overdose of anesthesia, and a 15-
min transmission scan with a Co-57 point source was acquired
for the correction of scatter and attenuation of 511 keV photons
by tissue. After the transmission scan, the animal remained fixed
to the bed, and the bed was positioned in a CT scanner
(MicroCAT II, CTI Siemens). A 15-min CT scan was acquired
for anatomic localization of the tumor (exposure time =
1050 ms; X-ray voltage = 55 kVp; anode current = 500 μA;
number of rotation steps = 500; total rotation = 360 °).
After completion of the imaging procedures, the tumors
were excised and weighted. Tumor samples were either
formalin-fixed paraffin embedded for immunohistochemical
analyses or snap frozen in liquid nitrogen and stored at −
80 °C for ex vivo Western blotting assays.
PET Data Analysis
Emission sinograms were iteratively reconstructed
(OSEM2D) after being normalized and corrected for
scattering, attenuation, and decay of radioactivity. The PET
and CT images were fused using Inveon Research Work-
place software (Siemens Preclinical Solution). For data
analysis, a volume of interest (VOI) was manually drawn
around the whole tumor on the CT image and transferred to
the corresponding PET image. A second VOI of the viable
part of the tumor was generated automatically using a region
growing method with a threshold of 50 % of the hottest pixel
in the tumor. The resulting VOIs were used to generate the
corresponding tracer accumulation in the viable part of the
tumor, expressed as kBq/cc, using Inveon Research Work-
place software. The tracer concentration was converted into
a maximum standardized uptake value (SUVmax), which was
defined as follows: [maximum tissue activity concentration
(Bq/cc) × body weight (g)/injected dose (Bq)] and assuming
a tissue density of 1 g/cc. To correct for non-specific
binding, correction for background was applied, using a VOI
in the contralateral shoulder muscle as background. The
background-corrected SUV was calculated as follows:
SUVcorr = SUVtumor–SUVmuscle.
Western Blotting
On average, 43 ± 15 mg tumor tissue was homogenized in
ice-cold commercial radio-immune precipitation assay
(RIPA) buffer (Pierce, lot# 89901) supplemented with
Complete-Mini Protease Inhibitor Tablets (Roche lot#
10810400). RIPA buffer was added in a 1:15 tissue-to-
buffer ratio. Samples were first ground using a motorized
tissue grinder, followed by sonication for 2 × 5 s. Samples
were vortexed and incubated for 45 min on a shaker and
subsequently centrifuged at 20841g for 20 min at 4 °C. The
clear supernatant was transferred to new tubes. The protein
concentrations were determined by Bradford assay and
standardized to 2.0 mg/ml by adding ice-cold RIPA buffer.
Samples were subsequently aliquoted and stored at − 80 °C
until further processing.
The frozen samples were thawed and mixed 4× with lithium
dodecyl sulfate (LDS) sample buffer (Life Technologies) and
dithiothreitol (DTT) as a reducing agent (Life technologies) in
the following ratio: sample:LDS:DTT = 0.65:0.25:0.10. Sam-
ples were mixed and heated for 10 min at 70 °C. Samples were
loaded and proteins were separated on Novex® Bolt Bis-Tris
4–12 % gradient gels (Life technologies, lot# 15031091) using
30 μg of total protein per well utilizing the 3-(N-
morpholino)propanesulfonic acid (MOPS) buffer system.
Proteins were transferred from gel to a 0.2-μm polyvinylidene
difluoride membrane (Life technologies), using the I-blot dry
blotting system (Life Technologies).
Membranes were blocked with 0.2 % I-block (Tropix)
and probed with rabbit-anti-C-erbβ-2, 1:500 (Thermo
Scientific; ref# RM_9103_S; lot#910351202E), mouse-
anti-ER-α (F10) (Santa Cruz; ref# sc-8002; lot# G0908),
and mouse-anti-β-actin 1:1000000 (MP-Biomedicals; ref#
08691002), followed by the secondary antibodies donkey-
anti-rabbit-horseradish peroxidase (HRP), 1:5000 (GE-
Healthcare; ref# NA934V), or goat anti-mouse-HRP (Santa-
Cruz; ref# SC-2005). Detection was done using standard
enhanced chemoluminescence (Thermo Fisher) in a
Chemidoc-XRS+ imaging system (Biorad). Quantification
was performed in the ImageLab 5.0 (Biorad). The protein of
interest was expressed as a fraction of the β-actin signal.
Immunohistochemical Analysis
Immunohistochemical analysis of the tumors treated with
trastuzumab (n = 2) or vehicle (n = 3) was performed to
confirm the changes in ER expression observed by
[18F]FES -PET. The immunohistochemical staining of
the formalin-fixed paraffin-embedded SKOV3 tumors
was performed according to the routine protocol for
clinical samples. ER-α rabbit monoclonal primary anti-
body (Clone SP-1, Ventana) and a c–erbB-2/HER-2/neu
rabbit monoclonal antibody (Clone SP-3, Thermo Fisher
scientific) were used for immunohistochemical staining of
ER-α and HER2, respectively. HER2 and ER immuno-
histochemistry results were analyzed by an expert histo-
pathologist according to a 4-level scoring system: 0, 1, 2,
and 3+ for no, weak, moderate, and high-intensity
staining, respectively.
Statistical Analysis
Statistical analyses were performed with Excel 2003
(Microsoft) and GraphPad Prism (version 5.04). Differ-
ences in tracer accumulation between vehicle controls and
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treated animals were analyzed using a two-sided unpaired
Student’s t test. Significance was reached when the
probability (P) was G 0.05. Throughout the manuscript,
values are presented as mean ± the standard deviation,
unless it is stated otherwise.
Results
Tumor Growth and Body Weight
The tumor size at the start of treatment did not differ
significantly between treatment (0.22 ± 0.15 cm3) and
control groups (0.16 ± 0.09 cm3, P = 0.59). All treatments
delayed tumor growth compared with the corresponding
control groups (Fig. 1a). None of the treatments caused
any severe side effects. Mice treated with lapatinib had a
significantly lower body weight than control animals on
day 10 and 12 of treatment, but at the time of the PET scan
(day 15), there was no significant difference in body
weight between the treatment and control group anymore
(Fig. 1b).
Pet
[18F]FES uptake in SKOV3 xenografts of mice treated with
trastuzumab (SUVmax 0.27 ± 0.02; P = 0.002) was approxi-
mately 29 % higher than that in controls (Fig. 2a, b).
[18F]FES uptake in the SKOV3 xenografts of lapatinib-
treated mice (SUVmax 0.25 ± 0.05) was also increased by
20 % compared with vehicle-treated controls (SUVmax 0.21
± 0.04), but this difference did not reach statistical signifi-
cance (P = 0.096). There was no significant difference
between animals treated with trastuzumab or lapatinib (P =
0.385). After correction of the tracer uptake for background,
the effects of treatment became even more pronounced. The
SUVcorr of [
18F]FES (Fig. 2c) was significantly higher in
both the trastuzumab-treated (0.14 ± 0.02, P = 0.0002) and
Fig. 1 a Relative tumor volume in nude mice where V(0) is the tumor volume before treatment and V(t) is the tumor volume at
the end of treatment. Six animals are unaccounted in this graph since their xenografts were not measurable at the beginning of
the treatment. b % Body weight of mice with a subcutaneous SKOV-3 xenograft during treatment with targeted anticancer
drugs (dashed line) and corresponding vehicle controls (solid line), considering the weight at the start of treatment as 100 %.
Results are expressed as mean ± SEM. Statistically significant differences compared with controls are indicated with *P G 0.05.
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the lapatinib-treated SKOV3 xenografts (0.14 ± 0.06, P =
0.024) than in non-treated controls (0.08 ± 0.03).
Western Blotting
Western blotting of the SKOV3 xenografts showed an
immunoreactive band for ERα at 66 kDa (Fig. 3a). For
HER2, immunoreactive bands were observed at 110 kDa for
the extracellular domain (HER2 ECD) and at 185 kDa for
the total receptor (HER2) (Fig. 3c). The ERα/β-actin ratio
found in trastuzumab-treated mice (0.86 ± 0.27) was 1.8
times higher than in controls (0.47 ± 0.25, P = 0.036) while
the ERα/β-actin ratio in lapatinib-treated mice (0.56 ± 0.36,
P = 0.604) was about 20 % higher than in controls, although
this effect did not reach statistical significance (Fig. 3b).
The HER2 expression levels in tumors obtained from mice
treated with trastuzumab (0.67 ± 0.58) were 2.3 times lower
that in controls (1.57 ± 0.75, P = 0.077) while the HER2/β-
actin ratio in lapatinib-treated mice (1.16 ± 0.42, P = 0.288)
was only 1.3 times lower than in controls (Fig. 3d).
Histology and Immunohistochemistry
The increase in ER expression after trastuzumab treatment
observed by PET imaging and Western blotting was
confirmed by immunohistochemistry. Tumor tissue
following trastuzumab treatment showed less viable tumor
cells. In the remaining viable cells, the HER2 staining
(Fig. 4b) was found to be less intense (score + 2) than in
untreated tumors (score + 3). However, ERα staining in the
remaining viable SKOV3 (Fig. 4a) tumor cells was more
intense (score + 2) than the staining of untreated SKOV3
tumors (score + 1).
Discussion
This study shows that [18F]FES-PET can detect changes of ER
expression in a preclinical xenograft model as a result of
inhibition of the HER2 signaling pathway with trastuzumab.
These results were supported by immunohistochemistry and
Western blotting. This is the first study in which crosstalk
between the HER2 and ER signaling pathways induced by
treatment was visualized and quantified noninvasively with PET.
Trastuzumab is a monoclonal antibody that binds to
HER2 and induces internalization and downregulation of the
receptor. In this study, we observed that trastuzumab
treatment can also affect the ER signaling pathway.
[18F]FES-PET showed approximately 29 % higher tracer
uptake (SUVmax) in SKOV3 xenografts of mice treated with
trastuzumab when compared with control mice. When
background correction was taken into account (SUVcorr),
the effect of treatment on specific tracer uptake was even
more pronounced (70 %), indicating a trastuzumab
Fig. 2 a Representative [18F]FES-PET-CT fusion image of a mouse bearing a SKOV3 xenograft treated with trastuzumab. The
tumor is delineated by the red region of interest. Quantitative 18F-FES uptake (b) as SUVmax and (c) as SUVcorr in SKOV3
xenografts of mice treated with trastuzumab, lapatinib, or vehicle (n represents the number of animals). Statistically significant
differences P G 0.05 or P G 0.001 compared with controls are indicated with * or **, respectively.
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treatment-induced increase in ER expression. In this study,
we did not perform full pharmacokinetic modeling of 18F-
FES uptake but derived the SUV from a static scan.
Theoretically, the SUV is sensitive to changes in several
physiological parameters, and the effect of trastuzumab
treatment on the [18F]FES uptake may, therefore, be affected
by a trastuzumab-induced increase in tumor perfusion (tracer
delivery) or decrease in tracer metabolism. In addition, the
ex vivo analysis of the tumors by Western blotting and
immunohistochemical staining confirmed the treatment-
induced increase in ERα expression.
Lapatinib can inhibit downstream HER2 signaling by
antagonizing the kinase activity of HER2, leading to
inhibition of cell proliferation and apoptosis induction and
antitumor activity in patients [12, 13]. However, part of the
patients is resistance to lapatinib treatment, and among the
ones that do respond to the treatment, the disease will
eventually progress. Wang et al. found that lapatinib may
induce the activation of an alternative pathway, such as ER-
mediated signaling which could cause resistance to lapatinib
treatment in HER2-positive breast cancer cells [14]. There-
fore, we investigated if lapatinib treatment-induced changes
in ER receptor expression could be detected by PET with the
tracer [18F]FES. In this study, 14-day lapatinib treatment
resulted in 54 % growth reduction of the SKOV3 xenografts
and a 20 % increase in [18F]FES uptake (SUVmax) in
SKOV3 xenografts, although these effects were not statisti-
cally significant (P = 0.09). The lack of significance could be
due to the high inter-subject variability. However, it seems
more likely that lapatinib had an effect on the non-specific
uptake of the tracer. In fact, we observed that background
[18F]FES uptake in the contralateral muscle was significantly
lower in the lapatinib-treated group than in controls, which
suggests that lapatinib could have affected [18F]FES clear-
ance from circulation (data not shown). When [18F]FES
uptake was corrected for background, lapatinib-treated
xenografts showed significantly higher specific tracer uptake
(SUVcorr) than in non-treated xenografts. Lapatinib-induced
changes in [18F]FES uptake appear to be in agreement with
our ex vivo analyses, as Western blotting also indicated a
high variability between tumors and a (statistically not
significant) 20 % increase in ER expression.
In our preclinical study, [18F]FES uptake in SKOV3
xenografts (SUVmax 0.21–0.27) was relatively low when
compared with tracer uptake in the breast or ovarian cancer
in patients (SUV 1.5–6.0) [15, 16]. Such low [18F]FES
uptake was also observed in other preclinical studies in
tumor-bearing mice [17, 18]. A plausible cause for the low
Fig. 3 A representative example of the Western blot analysis of ERα (a) or HER2 (c) in SKOV-3 tumor xenografts from mice
treated with trastuzumab (T), lapatinib (L), or vehicle (C). Western blot analysis of (b) ERα to β-actin protein ratio and (d) full-
length HER2 to β-actin protein ratio in SKOV-3 tumor xenografts (n represents the number of mice). Statistically significant
differences P G 0.05 compared with controls are indicated with *.
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uptake of [18F]FES in this study is the relatively low
expression of ER in the SKOV3 tumor cell line (ca.
830 fmol/mg of protein) compared with, for example, the
frequently used ER-expressing MCF7 breast tumor cell line
(ca. 1900 fmol/mg of protein) [18, 19].
A limitation of our study was the relatively small number
of animals per treatment, especially taking the high inter-
subject variability in tumor growth and treatment response
into account. Repetitive imaging could help to overcome this
hurdle, as it would enable the assessment of the changes in
receptor expression within a single animal over time. This
would increase the statistical power of the study, as the data
could be analyzed by paired tests.
Another limitation is that we only tested the SKOV3
xenograft model in a male mice model to show proof-of-
concept. Ideally, our findings should be confirmed in a
more relevant model, such as a xenograft model in
ovariectomized female mice, preferably using tumor cells
that express higher amounts of both ER and HER2
(HER2+/ER+), such as BT474 breast cancer cells.
However, we have now shown proof-of-concept, and
considering that PET is a highly translational technique,
confirmation of our findings can also be obtained
directly in cancer patients. [18F]FES-PET was already
shown to be able to detect ER expression in the tumors
of patients with epithelial ovarian cancer and thus may
also be used for the detection of treatment-induced
crosstalk between HER2 and ER in cancer patients.
A potential concern for assessing ER expression in
ovarian cancer patients could be the location of the tumor
in the abdominal area where visualization can be hampered
by the high physiological background uptake of [18F]FES in
the liver, gallbladder, intestines, ovaries, and bladder [20].
Despite this limitation, [18F]-FES-PET/CT was shown to
have a high sensitivity and specificity (79 % and 100 %) in
patients with epithelial ovarian cancer, comparable with its
performance in patients with metastasized breast cancer
(sensitivity 84 %; specificity 98 %) [20]. [18F]FES-PET can
thus be expected to be sufficiently sensitive and specific to
study ER-HER2 crosstalk in patients with ovarian cancer,
especially in solid tumors larger than 10 mm. For diffuse
tumors and solid tumors with smaller dimensions, this will
remain challenging. Needless to say, [18F]FES-PET could
also be used to evaluate treatment-induced crosstalk between
the ER and HER2 signaling pathways in breast cancer
patients.
Conclusion
This proof-of-concept study shows that PET imaging with
[18F]FES could be used to visualize and quantify the
treatment-induced crosstalk between the ER and HER2
signaling pathways in a preclinical cancer model. Since the
same PET method can be used in humans, this technique can
be applied to translate preclinical findings on the crosstalk
between signaling pathways into a clinical setting.
Fig. 4 Representative example of the immunohistochemical analysis of ERα (a) or HER2 (b) expression in SKOV-3 tumor
xenografts from vehicle-treated control mice and mice treated with trastuzumab, × 20 magnification.
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